MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:MDP - CA58410Q2036 - Common Stock
2.81 CAD
+0.06 (+2.18%)
Overall MDP gets a fundamental rating of 5 out of 10. We evaluated MDP against 35 industry peers in the Pharmaceuticals industry. MDP has an average financial health and profitability rating. MDP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year MDP was profitable.
- MDP had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MDP reported negative net income in multiple years.
- The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
- MDP has a better Return On Assets (0.25%) than 71.43% of its industry peers.
- MDP has a Return On Equity of 0.73%. This is in the better half of the industry: MDP outperforms 74.29% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 5.79%, MDP belongs to the top of the industry, outperforming 82.86% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for MDP is in line with the industry average of 8.45%.
- The 3 year average ROIC (9.89%) for MDP is well above the current ROIC(5.79%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 0.73% | ||
| ROIC | 5.79% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of MDP (0.37%) is better than 71.43% of its industry peers.
- MDP has a Operating Margin of 5.76%. This is in the better half of the industry: MDP outperforms 74.29% of its industry peers.
- MDP's Gross Margin of 53.01% is amongst the best of the industry. MDP outperforms 82.86% of its industry peers.
- MDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.76% | ||
| PM (TTM) | 0.37% | ||
| GM | 53.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDP is creating some value.
- The number of shares outstanding for MDP has been increased compared to 1 year ago.
- Compared to 5 years ago, MDP has more shares outstanding
- MDP has a better debt/assets ratio than last year.
2.2 Solvency
- MDP has an Altman-Z score of 0.55. This is a bad value and indicates that MDP is not financially healthy and even has some risk of bankruptcy.
- With a decent Altman-Z score value of 0.55, MDP is doing good in the industry, outperforming 62.86% of the companies in the same industry.
- The Debt to FCF ratio of MDP is 1.57, which is an excellent value as it means it would take MDP, only 1.57 years of fcf income to pay off all of its debts.
- MDP's Debt to FCF ratio of 1.57 is amongst the best of the industry. MDP outperforms 91.43% of its industry peers.
- MDP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- With an excellent Debt to Equity ratio value of 0.00, MDP belongs to the best of the industry, outperforming 88.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.57 | ||
| Altman-Z | 0.55 |
ROIC/WACC0.63
WACC9.15%
2.3 Liquidity
- MDP has a Current Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- MDP has a Current ratio of 0.83. This is amonst the worse of the industry: MDP underperforms 82.86% of its industry peers.
- MDP has a Quick Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of MDP (0.38) is worse than 82.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.38 |
3. Growth
3.1 Past
- MDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.89%.
- The Revenue has decreased by -0.63% in the past year.
- The Revenue has been growing slightly by 7.82% on average over the past years.
EPS 1Y (TTM)-88.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-317.78%
Revenue 1Y (TTM)-0.63%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-5.94%
3.2 Future
- MDP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.29% yearly.
- Based on estimates for the next years, MDP will show a quite strong growth in Revenue. The Revenue will grow by 10.06% on average per year.
EPS Next Y-169.44%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue Next Year-8.08%
Revenue Next 2Y4.36%
Revenue Next 3Y7.5%
Revenue Next 5Y10.06%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- MDP is valuated quite expensively with a Price/Earnings ratio of 281.00.
- Compared to the rest of the industry, the Price/Earnings ratio of MDP indicates a somewhat cheap valuation: MDP is cheaper than 68.57% of the companies listed in the same industry.
- MDP's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.47.
- A Price/Forward Earnings ratio of 10.00 indicates a reasonable valuation of MDP.
- 82.86% of the companies in the same industry are more expensive than MDP, based on the Price/Forward Earnings ratio.
- MDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.26.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 281 | ||
| Fwd PE | 10 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 88.57% of the companies listed in the same industry.
- 91.43% of the companies in the same industry are more expensive than MDP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.87 | ||
| EV/EBITDA | 5.04 |
4.3 Compensation for Growth
- MDP has a very decent profitability rating, which may justify a higher PE ratio.
- MDP's earnings are expected to grow with 77.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.9%
EPS Next 3Y77.1%
5. Dividend
5.1 Amount
- No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MDP (1/16/2026, 7:00:00 PM)
2.81
+0.06 (+2.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)02-05 2026-02-05
Inst Owners3.25%
Inst Owner ChangeN/A
Ins Owners7.59%
Ins Owner ChangeN/A
Market Cap91.10M
Revenue(TTM)104.10M
Net Income(TTM)381.00K
Analysts82.5
Price Target6.3 (124.2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.5%
Min EPS beat(2)0.99%
Max EPS beat(2)144%
EPS beat(4)4
Avg EPS beat(4)68.3%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)6
Avg EPS beat(8)45.18%
EPS beat(12)9
Avg EPS beat(12)93.03%
EPS beat(16)11
Avg EPS beat(16)69.35%
Revenue beat(2)0
Avg Revenue beat(2)-2.42%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)0.38%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)6.82%
Revenue beat(8)2
Avg Revenue beat(8)-2.53%
Revenue beat(12)4
Avg Revenue beat(12)-1.12%
Revenue beat(16)8
Avg Revenue beat(16)1.52%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-500%
EPS NY rev (1m)0%
EPS NY rev (3m)-340%
Revenue NQ rev (1m)-4.92%
Revenue NQ rev (3m)-4.84%
Revenue NY rev (1m)-0.28%
Revenue NY rev (3m)-2.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 281 | ||
| Fwd PE | 10 | ||
| P/S | 0.63 | ||
| P/FCF | 4.87 | ||
| P/OCF | 4.03 | ||
| P/B | 1.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.04 |
EPS(TTM)0.01
EY0.36%
EPS(NY)0.28
Fwd EY10%
FCF(TTM)0.58
FCFY20.53%
OCF(TTM)0.7
OCFY24.79%
SpS4.46
BVpS2.25
TBVpS-1.06
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 0.73% | ||
| ROCE | 8.05% | ||
| ROIC | 5.79% | ||
| ROICexc | 6.63% | ||
| ROICexgc | N/A | ||
| OM | 5.76% | ||
| PM (TTM) | 0.37% | ||
| GM | 53.01% | ||
| FCFM | 12.92% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.57 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 30.83% | ||
| Cap/Sales | 2.68% | ||
| Interest Coverage | 1.96 | ||
| Cash Conversion | 107.99% | ||
| Profit Quality | 3530.97% | ||
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.38 | ||
| Altman-Z | 0.55 |
F-Score5
WACC9.15%
ROIC/WACC0.63
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-317.78%
EPS Next Y-169.44%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-0.63%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-5.94%
Revenue Next Year-8.08%
Revenue Next 2Y4.36%
Revenue Next 3Y7.5%
Revenue Next 5Y10.06%
EBIT growth 1Y-53.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.54%
EBIT Next 3Y65.62%
EBIT Next 5Y51.32%
FCF growth 1Y3.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.81%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MDP.CA.
What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a valuation rating of 6 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 6 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.